BLACK NOVEMBERSAVE 45%Discover more. Spend less.
Research

Melanotan II (MT-2): Melanocortin Receptor Agonism and the Science of Pigmentation Research

Melanotan II is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective agonist at melanocortin receptors MC1R through MC5R. A Phase I clinical study published in Life Sciences established its tanning activity in humans, while subsequent research has explored its diverse pharmacological effects across multiple receptor subtypes.

10 March 202511 min readBionexis Research Team

Introduction: From Natural Hormone to Synthetic Analogue

Melanotan II (MT-2) was developed in the 1980s and 1990s at the University of Arizona by a team led by Victor Hruby and Mac Hadley, with the goal of creating a stable, potent synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that could be studied in clinical settings. The natural hormone α-MSH is a 13-amino acid peptide derived from pro-opiomelanocortin (POMC) that regulates skin pigmentation, energy homeostasis, sexual function, and inflammation through its actions on melanocortin receptors.

MT-2 is a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) that was engineered to be more potent and metabolically stable than the natural α-MSH. The cyclisation and incorporation of D-phenylalanine at position 7 confer resistance to enzymatic degradation and increase receptor binding affinity. These structural modifications make MT-2 a valuable research tool for investigating melanocortin receptor pharmacology across all five receptor subtypes (MC1R–MC5R) [1].

Melanocortin Receptor Pharmacology

The five melanocortin receptor subtypes are distributed throughout the body and mediate distinct physiological functions. Understanding MT-2's interaction with each subtype is essential for interpreting its research profile:

MC1R is expressed primarily on melanocytes in the skin and is the principal mediator of pigmentation. Activation of MC1R stimulates the production of eumelanin — the dark brown/black pigment that provides photoprotection — over pheomelanin, the reddish-yellow pigment associated with increased UV sensitivity. MC1R is also expressed on immune cells, where it mediates anti-inflammatory effects.

MC2R is expressed almost exclusively in the adrenal cortex and mediates the stimulation of cortisol synthesis by ACTH. MT-2 has low affinity for MC2R, which limits its effects on the hypothalamic-pituitary-adrenal axis.

MC3R and MC4R are expressed in the brain and are involved in energy homeostasis, appetite regulation, and sexual function. MC4R in particular is a major regulator of food intake and body weight, and its activation contributes to the appetite-suppressing effects observed with melanocortin agonists.

MC5R is expressed in exocrine glands and is involved in the regulation of sebaceous gland function and other secretory processes [2].

Phase I Clinical Evidence: The Arizona Study

The foundational clinical study of MT-2 in humans was published by Dorr et al. (1996) in Life Sciences and has been cited over 193 times. This Phase I study evaluated MT-2 in healthy volunteers using a subcutaneous injection protocol of five low doses administered every other day. The results demonstrated that MT-2 has tanning activity in humans at these doses, with increased skin pigmentation observed in treated participants compared to controls [3].

The study also documented the adverse event profile of MT-2 at these doses, which included nausea, flushing, and spontaneous penile erection — the latter reflecting MC4R activation in the central nervous system. These findings established the pharmacodynamic profile of MT-2 in humans and provided the safety data that underpins subsequent research with this compound.

Photoprotection Research

One of the most scientifically significant potential applications of MC1R agonism is photoprotection — the enhancement of the skin's natural defence against ultraviolet radiation. Sivyer et al. (2012), publishing in a study cited over 21 times, found that Melanotan 2 increased skin pigmentation at lower cumulative doses than Melanotan 1, and that the resulting pigmentation provided a degree of photoprotective benefit [4].

Research by Wu et al. (2020), published in Frontiers in Oncology and cited over 9 times, investigated the effects of topical MT-2 therapy on melanoma progression, finding that MT-2 elicits PTEN upregulation via MC1R, thereby suppressing melanoma progression through downregulation of the COX-2/PGE2 signalling pathway — a finding with potential implications for skin cancer research [5].

Metabolic and Appetite Research

MT-2's activation of MC3R and MC4R in the hypothalamus has been shown to increase metabolic rate and decrease food intake in preclinical models. Research reviewed on ScienceDirect notes that Melanotan II has been shown to increase metabolic rate and decrease food intake in wild-type mice, consistent with the known role of central melanocortin signalling in energy homeostasis regulation. These findings position MT-2 as a research tool for investigating the neural circuits that regulate appetite and body weight.

Research Context and Regulatory Considerations

It is important to note that MT-2 is a research compound and is not approved for human use by the FDA, EMA, or MHRA. The Phase I clinical data provides safety information at specific doses in controlled research settings, but MT-2 has not completed the clinical development process required for therapeutic approval. All research with MT-2 should be conducted within appropriate regulatory frameworks and ethical oversight.

The compound's non-selective activity across multiple melanocortin receptor subtypes means that research findings must be interpreted with awareness of the multiple physiological systems that may be engaged simultaneously. Selective MC1R agonists are under investigation as potentially more targeted research tools, but MT-2 remains valuable for research into the integrated physiology of the melanocortin system.

Purity Requirements for Research

MT-2 is a cyclic heptapeptide with a molecular weight of 1,024.2 Da. Its cyclic structure requires careful synthesis to ensure correct disulphide bond formation and ring closure. Research-grade MT-2 should be verified by HPLC to a minimum purity of 98%, with mass spectrometry confirmation of the correct molecular weight and circular dichroism or NMR verification of the correct cyclic structure where possible.

Conclusion

Melanotan II occupies a unique position in peptide research as a non-selective melanocortin receptor agonist with documented human clinical data from Phase I trials. Its pharmacological profile — spanning pigmentation, photoprotection, energy homeostasis, and sexual function through its actions on MC1R–MC5R — makes it a versatile research tool for investigating the melanocortin system. The foundational Phase I study by Dorr et al. (1996), cited over 193 times, remains the cornerstone of human safety data for this compound, while subsequent research has continued to expand understanding of its diverse receptor-mediated effects.

References

  1. [1] Hruby VJ et al. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides (2005). DOI: 10.1016/j.peptides.2005.01.029.View Source
  2. [2] Wikberg JE et al. "Melanocortin receptors: perspectives for novel drugs." European Journal of Pharmacology (2000). DOI: 10.1016/S0014-2999(00)00441-1.View Source
  3. [3] Dorr RT et al. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sciences (1996). DOI: 10.1016/0024-3205(96)00160-9.View Source
  4. [4] Sivyer GW et al. "Changes of melanocytic lesions induced by Melanotan II." Journal of the European Academy of Dermatology and Venereology (2012). DOI: 10.1111/j.1468-3083.2011.04359.x.View Source
  5. [5] Wu JC et al. "Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Inhibition of COX-2/PGE2 Signaling." Frontiers in Oncology (2020). DOI: 10.3389/fonc.2020.00057.View Source
B

Bionexis Research Team

Peptide Science & Quality Assurance Division

The Bionexis Research Team reviews and synthesises published scientific literature to provide accurate, evidence-based information for the peptide research community. All articles undergo editorial review to ensure factual accuracy and proper citation of peer-reviewed sources.

Research Use Disclaimer: This article is provided for informational and educational purposes only. All peptides referenced are intended for laboratory research use only and are not intended for human consumption. The information presented is based on published scientific studies and does not constitute medical advice. Always consult qualified professionals for health-related decisions.

Need High-Purity Research Peptides?

Bionexis Peptides supplies ≥99% purity research peptides, independently tested by Janoshik Analytical. Every batch comes with a full Certificate of Analysis.